Aspire Biopharma Holdings, Inc. 8-KCurrent Reports (8-K / ad hoc)

Changes / Accountants

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated September 8, 2026 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). Field: Page; Sequence: 2 Field: /Page SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRE BIOPHARMA HOLDINGS, INC. By: /s/ Kraig Higginson Kraig Higginson Chief Executive Officer Date: September 8, 2026 Field: Page; Sequence: 3; Options: Last Field: /Page Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kU1uwjAQhU/AHUZRlxE4kYra7GgUUFUoCCrarTGTYpF4orGhcKTeso5TBIvWsuS/+d57I0dRHE1orCtk+HhaTuEN66aSDmGJJTIahb4if37JwK9L/NTWsTQuHC9gTp5Bzwz798rfh8qjtrjNQDwOxMMgHfpNlggYzaJe+56TKfUWjdOyAmm2sGBqWKOTfO4U3uSJDNXn4LRGtppMBklfdM/fkIokhVc6yi/ivYXpNI96cRi9aMJ0aHxVcXJoWhKKCmtvZzv6OkMadbCO6uxdctubLaTaFSdkpa3cVDgmnhtc7STjvPS91mRWjtR+hvUG2eOJSNNEjH6TXVRiQK8DeBWCkhjIINhWC6gEFdTAtnJ/BLoxW0hey+qAoi+ESBbIIc8/EfIb2RgayXBsWbjraGj8p4UMF88ftgiePA==